Modeling within-host viral dynamics: The role of CTL immune responses in the evolution of drug resistance

Qi Deng; Zhipeng Qiu; Ting Guo; Libin Rong

doi:10.3934/dcdsb.2020245

Previous Article
Global strong solution and exponential decay for nonhomogeneous Navier-Stokes and magnetohydrodynamic equations
DCDS-B Home
This Issue
Next Article
Regular dynamics for stochastic Fitzhugh-Nagumo systems with additive noise on thin domains

July 2021, 26(7): 3543-3562. doi: 10.3934/dcdsb.2020245

Modeling within-host viral dynamics: The role of CTL immune responses in the evolution of drug resistance

Qi Deng ^1, , Zhipeng Qiu ^1,, , Ting Guo ^1, and Libin Rong ^2,

1.	Department of Mathematics, Nanjing University of Science and Technology, Nanjing 210094, China
2.	Department of Mathematics, University of Florida, Gainesville, FL 32611, USA

^* Corresponding author: Zhipeng Qiu

Received February 2020 Revised June 2020 Published July 2021 Early access August 2020

Fund Project: T. Guo was supported by the CSC (201806840119) and the NSFC (11971232). Z. Qiu was supported by the NSFC (11671206). L. Rong was supported by the NSF Grant DMS-1758290

To study the emergence and evolution of drug resistance during treatment of HIV infection, we study a mathematical model with two strains, one drug-sensitive and the other drug-resistant, by incorporating cytotoxic T lymphocyte (CTL) immune response. The reproductive numbers for each strain with and without the CTL immune response are obtained and shown to determine the stability of the steady states. By sensitivity analysis, we evaluate how the changes of parameters influence the reproductive numbers. The model shows that CTL immune response can suppress the development of drug resistance. There is a dynamic relationship between antiretroviral drug administration, the prevalence of drug resistance, the total level of viral production, and the strength of immune responses. We further investigate the scenario under which the drug-resistant strain can outcompete the wild-type strain. If drug efficacy is at an intermediate level, the drug-resistant virus is likely to arise. The slower the immune response wanes, the slower the drug-resistant strain grows. The results suggest that immunotherapy that aims to enhance immune responses, combined with antiretroviral drug treatment, may result in a functional control of HIV infection.

Erratum: The affiliations of Ting Guo and Libin Rong have been corrected to show that only Ting Guo is affiliated to Nanjing University of Science and Technology and only Libin Rong is affiliated to the University of Florida. We apologize for any inconvenience this may cause.

Keywords: Drug resistance, antiretroviral therapy, CTL immune response, sensitivity analysis, Stability.

Mathematics Subject Classification: 03C25, 34D20, 34D08, 37C75.

Citation: Qi Deng, Zhipeng Qiu, Ting Guo, Libin Rong. Modeling within-host viral dynamics: The role of CTL immune responses in the evolution of drug resistance. Discrete and Continuous Dynamical Systems - B, 2021, 26 (7) : 3543-3562. doi: 10.3934/dcdsb.2020245

References:

[1]	B. M. Adams, H. T. Banks, M. Davidian, H.-D. Kwon, H. T. Tran, S. N. Wynne and E. S. Rosenberg, HIV dynamics: Modeling, data analysis, and optimal treatment protocols, J. Comput. Appl. Math., 184 (2005), 10-49. doi: 10.1016/j.cam.2005.02.004.
[2]	K. Allali, J. Danane and Y. Kuang, Global analysis for an HIV infection model with CTL immune response and infected cells in eclipse phase, Appl. Sci., 7 (2017), 861.
[3]	R. A. Arnaout, N. Martin A and D. Wodarz, HIV-1 dynamics revisited: Biphasic decay by Cytotoxic T Lymphocyte killing?, Proc. R. Soc. Lond. B, 267 (2000), 1347-1354. doi: 10.1098/rspb.2000.1149.
[4]	N. P. Bhatia and G. P. Szegö, Stability Theory of Dynamical Systems, Springer Science & Business Media, 2002.
[5]	S. M. Blower, D. Hartel, H. Dowlatabadi, R. M. Anderson and R. M. May, Drugs, sex and HIV: A mathematical model for New York City, Proc. R. Soc. Lond. B, 331 (1991), 171-187.
[6]	S. Bonhoeffer, R. M. May, G. M. Shaw and M. A. Nowak, Virus dynamics and drug therapy, P. Natl. A. Sci., 94 (1997), 6971-6976. doi: 10.1073/pnas.94.13.6971.
[7]	J. Cao, J. McNevin, S. Holte, L. Fink, L. Corey and M. J. McElrath, Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection, J. Virol., 77 (2003), 6867-6878. doi: 10.1128/JVI.77.12.6867-6878.2003.
[8]	H. Y. Chen, M. Di Mascio, A. S. Perelson, D. D. Ho and L. Zhang, Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques, P. Natl. A. Sci., 104 (2007), 19079-19084. doi: 10.1073/pnas.0707449104.
[9]	M. Ciupe, B. Bivort, D. Bortz and P. Nelson, Estimating kinetic parameters from HIV primary infection data through the eyes of three different mathematical models, Math. Biosci., 200 (2006), 1-27. doi: 10.1016/j.mbs.2005.12.006.
[10]	F. Clavel and A. J. Hance, HIV drug resistance, New. Engl. J. Med., 350 (2004), 1023-1035. doi: 10.1056/NEJMra025195.
[11]	R. V. Culshaw, S. Ruan and R. J. Spiteri, Optimal HIV treatment by maximising immune response, J. Math. Biol., 48 (2004), 545-562. doi: 10.1007/s00285-003-0245-3.
[12]	M. P. Davenport, R. M. Ribeiro and A. S. Perelson, Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection, J. Virol., 78 (2004), 10096-10103. doi: 10.1128/JVI.78.18.10096-10103.2004.
[13]	M. P. Davenport, R. M. Ribeiro, L. Zhang, D. P. Wilson and A. S. Perelson, Understanding the mechanisms and limitations of immune control of HIV, Immunlo. Rev., 216 (2007), 164-175. doi: 10.1017/CBO9780511818097.
[14]	M. P. Davenport, High-potency human immunodeficiency virus vaccination leads to delayed and reduced CD8+ T-cell expansion but improved virus control, J. Virol., 79 (2005), 10059-10062. doi: 10.1128/JVI.79.15.10059-10062.2005.
[15]	S. G. Deeks, M. Smith, M. Holodniy and J. O. Kahn, HIV-1 protease inhibitors: A review for clinicians, Jama, 277 (1997), 145-153. doi: 10.1001/jama.1997.03540260059037.
[16]	P. Dubey, U. S. Dubey and B. Dubey, Modeling the role of acquired immune response and antiretroviral therapy in the dynamics of HIV infection, Math. Comput. Simulat., 144 (2018), 120-137. doi: 10.1016/j.matcom.2017.07.006.
[17]	M. A. Gilchrist, D. Coombs and A. S. Perelson, Optimizing within-host viral fitness: Infected cell lifespan and virion production rate, J. Theor. Biol., 229 (2004), 281-288. doi: 10.1016/j.jtbi.2004.04.015.
[18]	T. Guo and Z. Qiu, The effects of CTL immune response on HIV infection model with potent therapy, latently infected cells and cell-to-cell viral transmission, doi: 10.3934/mbe.2019341.
[19]	T. Guo, Z. Qiu and L. Rong, Analysis of an hiv model with immune responses and cell-to-cell transmission, Bull. Malays. Math. Sci. So., 43 (2020), 581-607. doi: 10.1007/s40840-018-0699-5.
[20]	S. A. Kalams, P. J. Goulder, A. K. Shea, N. G. Jones, A. K. Trocha, G. S. Ogg and B. D. Walker, Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy, J. Virol., 73 (1999), 6721-6728. doi: 10.1128/JVI.73.8.6721-6728.1999.
[21]	D. E. Kirschner and G. Webb, Understanding drug resistance for monotherapy treatment of HIV infection, Bull. Math. Biol., 59 (1997), 763-785. doi: 10.1007/BF02458429.
[22]	R. Koup, J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing and D. D. Ho, Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome, J. Virol., 68 (1994), 4650-4655. doi: 10.1128/JVI.68.7.4650-4655.1994.
[23]	M. Louie, Determining the relative efficacy of highly active antiretroviral therapy, J.Infect. Dis., 187 (2003), 896-900. doi: 10.1086/368164.
[24]	L. M. Mansky and H. M. Temin, Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase, J. Virol., 69 (1995), 5087-5094. doi: 10.1128/JVI.69.8.5087-5094.1995.
[25]	S. Marino, I. B. Hogue, C. J. Ray and D. E. Kirschner, A methodology for performing global uncertainty and sensitivity analysis in systems biology, J. Theor. Biol., 254 (2009), 178-196. doi: 10.1016/j.jtbi.2008.04.011.
[26]	R. D. Mason, M. I. Bowmer, C. M. Howley, M. Gallant, J. C. Myers and M. D. Grant, Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 pol epitopes, J. Immunol., 172 (2004), 7212-7219. doi: 10.4049/jimmunol.172.11.7212.
[27]	A. R. McLean and M. A. Nowak, Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV, Aids, 6 (1992), 71-79. doi: 10.1097/00002030-199201000-00009.
[28]	S. H. Michaels, R. Clark and P. Kissinger, Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, New. Engl. J. Med., 339 (1998), 405-406. doi: 10.1056/NEJM199808063390612.
[29]	P. Ngina, R. W. Mbogo and L. S. Luboobi, HIV drug resistance: Insights from mathematical modelling, Appl. Math. Model., 75 (2019), 141-161. doi: 10.1016/j.apm.2019.04.040.
[30]	M. Nowak and R. M. May, Virus Dynamics: Mathematical Principles of Immunology and Virology: Mathematical Principles of Immunology and Virology, Oxford University Press, UK, 2000.
[31]	M. A. Nowak and C. R. Bangham, Population dynamics of immune responses to persistent viruses, Science, 272 (1996), 74-79. doi: 10.1126/science.272.5258.74.
[32]	M. A. Nowak and R. M. May, Mathematical biology of HIV infections: Antigenic variation and diversity threshold, Math. Biosci., 106 (1991), 1-21. doi: 10.1016/0025-5564(91)90037-J.
[33]	M. A. Nowak and A. J. McMichael, How HIV defeats the immune system, Sci. AM., 273 (1995), 58-65. doi: 10.1038/scientificamerican0895-58.
[34]	A. S. Perelson, D. E. Kirschner and R. De Boer, Dynamics of HIV infection of CD4+ T cells, Math. Biosci., 114 (1993), 81-125. doi: 10.1016/0025-5564(93)90043-A.
[35]	A. S. Perelson, A. U. Neumann, M. Markowitz, J. M. Leonard and D. D. Ho, HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time, Science, 271 (1996), 1582-1586. doi: 10.1126/science.271.5255.1582.
[36]	A. S. Perelson and R. M. Ribeiro, Modeling the within-host dynamics of HIV infection, BMC Biol., 11 (2013), 96. doi: 10.1186/1741-7007-11-96.
[37]	Z. Qiu and Z. Feng, The dynamics of an epidemic model with targeted antiviral prophylaxis, J. Biol. Dyn., 4 (2010), 506-526. doi: 10.1080/17513758.2010.498925.
[38]	S. M. Raimundo, H. M. Yang, E. Venturino and E. Massad, Modeling the emergence of HIV-1 drug resistance resulting from antiretroviral therapy: Insights from theoretical and numerical studies, BioSystems, 108 (2012), 1-13. doi: 10.1016/j.biosystems.2011.11.009.
[39]	B. Ramratnam and et al., Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis, The Lancet, 354 (1999), 1782-1785. doi: 10.1016/S0140-6736(99)02035-8.
[40]	R. M. Ribeiro and S. Bonhoeffer, Production of resistant HIV mutants during antiretroviral therapy, P. Natl. A. Sci., 97 (2000), 7681-7686. doi: 10.1073/pnas.97.14.7681.
[41]	R. M. Ribeiro, S. Bonhoeffer and M. A. Nowak, The frequency of resistant mutant virus before antiviral therapy, Aids, 12 (1998), 461-465. doi: 10.1097/00002030-199805000-00006.
[42]	L. Rong, Z. Feng and A. S. Perelson, Emergence of HIV-1 drug resistance during antiretroviral treatment, Bull. Math. Biol., 69 (2007), 2027-2060. doi: 10.1007/s11538-007-9203-3.
[43]	L. Rong, Z. Feng and A. S. Perelson, Mathematical modeling of HIV-1 infection and drug therapy, Math. Model. Bios., 87-131. doi: 10.1007/978-3-540-76784-8_3.
[44]	L. Rong, M. A. Gilchrist, Z. Feng and A. S. Perelson, Modeling within-host HIV-1 dynamics and the evolution of drug resistance: Trade-offs between viral enzyme function and drug susceptibility, J. Theor. Biol., 247 (2007), 804-818. doi: 10.1016/j.jtbi.2007.04.014.
[45]	L. Rong and A. S. Perelson, Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips, Math. Biosci., 217 (2009), 77-87. doi: 10.1016/j.mbs.2008.10.006.
[46]	B. Sebastian and A. N. Martin, Pre-existence and emergence of drug resistance in HIV-1 infection, Proc. R. Soc. Lond. B, 264 (1997), 631-637. doi: 10.1098/rspb.1997.0089.
[47]	A. K. Sewell, D. A. Price, A. Oxenius, A. D. Kelleher and R. E. Phillips, Cytotoxic T Lymphocyte responses to human immunodeficiency virus: Control and escape, Stem Cells, 18 (2000), 230-244. doi: 10.1634/stemcells.18-4-230.
[48]	T. Shiri, W. Garira and S. D. Musekwa, A two-strain hiv-1 mathematical model to assess the effects of chemotherapy on disease parameters, Math. Biosci. Eng., 2 (2005), 811. doi: 10.3934/mbe.2005.2.811.
[49]	M. O. Souza and J. P. Zubelli, Global stability for a class of virus models with Cytotoxic T Lymphocyte immune response and antigenic variation, Bull. Math. Biol., 73 (2011), 609-625. doi: 10.1007/s11538-010-9543-2.
[50]	N. Tarfulea and P. Read, A mathematical model for the emergence of HIV drug resistance during periodic bang-bang type antiretroviral treatment, Involve, J. Math., 8 (2015), 401-420. doi: 10.2140/involve.2015.8.401.
[51]	P. Van den Driessche and J. Watmough, Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission, Math. Biosci., 180 (2002), 29-48. doi: 10.1016/S0025-5564(02)00108-6.
[52]	L. M. Wahl and M. A. Nowak, Adherence and drug resistance: Predictions for therapy outcome, Proc. Biol. Sci., 267 (2000), 835-843. doi: 10.1098/rspb.2000.1079.
[53]	K. Wang, W. Wang and X. Liu, Global stability in a viral infection model with lytic and nonlytic immune responses, Comput. Math. Appl., 51 (2006), 1593-1610. doi: 10.1016/j.camwa.2005.07.020.
[54]	K. Wang, W. Wang, H. Pang and X. Liu, Complex dynamic behavior in a viral model with delayed immune response, Physica D: Nonlinear Phenomena, 226 (2007), 197-208. doi: 10.1016/j.physd.2006.12.001.
[55]	X. Wang, A. Elaiw and X. Song, Global properties of a delayed HIV infection model with CTL immune response, Appl. Math. Comput., 218 (2012), 9405-9414. doi: 10.1016/j.amc.2012.03.024.
[56]	X. Wang, Y. Tao and X. Song, Global stability of a virus dynamics model with beddington-deangelis incidence rate and CTL immune response, Nonlinear Dyn., 66 (2011), 825-830. doi: 10.1007/s11071-011-9954-0.
[57]	Y. Wang, F. Brauer, J. Wu and J. M. Heffernan, A delay-dependent model with HIV drug resistance during therapy, J. Math. Anal. Appl., 414 (2014), 514-531. doi: 10.1016/j.jmaa.2013.12.064.
[58]	Y. Wang, Y. Zhou, F. Brauer and J. M. Heffernan, Viral dynamics model with CTL immune response incorporating antiretroviral therapy, J. Math. Biol., 67 (2013), 901-934. doi: 10.1007/s00285-012-0580-3.
[59]	R. A. Weiss, How does HIV cause AIDS?, Science, 260 (1993), 1273-1279. doi: 10.1126/science.8493571.
[60]	WHO, HIV/AIDS: Key facts, http://www.who.int/news-room/fact-sheets/detail/hiv-aids, 2018.
[61]	D. Wodarz and A. L. Lloyd, Immune responses and the emergence of drug-resistant virus strains in vivo, Proc. R. Soc. Lond. B, 271 (2004), 1101-1109.
[62]	D. Wodarz and M. A. Nowak, Specific therapy regimes could lead to long-term immunological control of HIV, P. Natl. A. Sci., 96 (1999), 14464-14469. doi: 10.1073/pnas.96.25.14464.
[63]	D. Wodarz and M. A. Nowak, Immune responses and viral phenotype: Do replication rate and cytopathogenicity influence virus load?, Comput. Math. Method. M., 2 (2000), 113-127. doi: 10.1080/10273660008833041.
[64]	D. Wodarz and M. A. Nowak, Mathematical models of HIV pathogenesis and treatment, BioEssays, 24 (2002), 1178-1187. doi: 10.1002/bies.10196.
[65]	J. Wu, P. Yan and C. Archibald, Modelling the evolution of drug resistance in the presence of antiviral drugs, BMC Public Health, 7 (2007), 300. doi: 10.1186/1471-2458-7-300.
[66]	J. Wu, R. Dhingra, M. Gambhir and J. V. Remais, Sensitivity analysis of infectious disease models: Methods, advances and their application, J. R. Soc. Interface, 10 (2013), 20121018. doi: 10.1098/rsif.2012.1018.
[67]	Y. Xiao, S. Tang, Y. Zhou, R. J. Smith, J. Wu and N. Wang, Predicting the HIV/AIDS epidemic and measuring the effect of mobility in mainland China, J. Theor. Biol., 317 (2013), 271-285. doi: 10.1016/j.jtbi.2012.09.037.
[68]	H. Zhu and X. Zou, Dynamics of a HIV-1 infection model with cell-mediated immune response and intracellular delay, Discrete Contin. Dyn. Syst. Ser. B, 12 (2009), 511-524. doi: 10.3934/dcdsb.2009.12.511.

show all references

References:

[1]	B. M. Adams, H. T. Banks, M. Davidian, H.-D. Kwon, H. T. Tran, S. N. Wynne and E. S. Rosenberg, HIV dynamics: Modeling, data analysis, and optimal treatment protocols, J. Comput. Appl. Math., 184 (2005), 10-49. doi: 10.1016/j.cam.2005.02.004.
[2]	K. Allali, J. Danane and Y. Kuang, Global analysis for an HIV infection model with CTL immune response and infected cells in eclipse phase, Appl. Sci., 7 (2017), 861.
[3]	R. A. Arnaout, N. Martin A and D. Wodarz, HIV-1 dynamics revisited: Biphasic decay by Cytotoxic T Lymphocyte killing?, Proc. R. Soc. Lond. B, 267 (2000), 1347-1354. doi: 10.1098/rspb.2000.1149.
[4]	N. P. Bhatia and G. P. Szegö, Stability Theory of Dynamical Systems, Springer Science & Business Media, 2002.
[5]	S. M. Blower, D. Hartel, H. Dowlatabadi, R. M. Anderson and R. M. May, Drugs, sex and HIV: A mathematical model for New York City, Proc. R. Soc. Lond. B, 331 (1991), 171-187.
[6]	S. Bonhoeffer, R. M. May, G. M. Shaw and M. A. Nowak, Virus dynamics and drug therapy, P. Natl. A. Sci., 94 (1997), 6971-6976. doi: 10.1073/pnas.94.13.6971.
[7]	J. Cao, J. McNevin, S. Holte, L. Fink, L. Corey and M. J. McElrath, Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection, J. Virol., 77 (2003), 6867-6878. doi: 10.1128/JVI.77.12.6867-6878.2003.
[8]	H. Y. Chen, M. Di Mascio, A. S. Perelson, D. D. Ho and L. Zhang, Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques, P. Natl. A. Sci., 104 (2007), 19079-19084. doi: 10.1073/pnas.0707449104.
[9]	M. Ciupe, B. Bivort, D. Bortz and P. Nelson, Estimating kinetic parameters from HIV primary infection data through the eyes of three different mathematical models, Math. Biosci., 200 (2006), 1-27. doi: 10.1016/j.mbs.2005.12.006.
[10]	F. Clavel and A. J. Hance, HIV drug resistance, New. Engl. J. Med., 350 (2004), 1023-1035. doi: 10.1056/NEJMra025195.
[11]	R. V. Culshaw, S. Ruan and R. J. Spiteri, Optimal HIV treatment by maximising immune response, J. Math. Biol., 48 (2004), 545-562. doi: 10.1007/s00285-003-0245-3.
[12]	M. P. Davenport, R. M. Ribeiro and A. S. Perelson, Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection, J. Virol., 78 (2004), 10096-10103. doi: 10.1128/JVI.78.18.10096-10103.2004.
[13]	M. P. Davenport, R. M. Ribeiro, L. Zhang, D. P. Wilson and A. S. Perelson, Understanding the mechanisms and limitations of immune control of HIV, Immunlo. Rev., 216 (2007), 164-175. doi: 10.1017/CBO9780511818097.
[14]	M. P. Davenport, High-potency human immunodeficiency virus vaccination leads to delayed and reduced CD8+ T-cell expansion but improved virus control, J. Virol., 79 (2005), 10059-10062. doi: 10.1128/JVI.79.15.10059-10062.2005.
[15]	S. G. Deeks, M. Smith, M. Holodniy and J. O. Kahn, HIV-1 protease inhibitors: A review for clinicians, Jama, 277 (1997), 145-153. doi: 10.1001/jama.1997.03540260059037.
[16]	P. Dubey, U. S. Dubey and B. Dubey, Modeling the role of acquired immune response and antiretroviral therapy in the dynamics of HIV infection, Math. Comput. Simulat., 144 (2018), 120-137. doi: 10.1016/j.matcom.2017.07.006.
[17]	M. A. Gilchrist, D. Coombs and A. S. Perelson, Optimizing within-host viral fitness: Infected cell lifespan and virion production rate, J. Theor. Biol., 229 (2004), 281-288. doi: 10.1016/j.jtbi.2004.04.015.
[18]	T. Guo and Z. Qiu, The effects of CTL immune response on HIV infection model with potent therapy, latently infected cells and cell-to-cell viral transmission, doi: 10.3934/mbe.2019341.
[19]	T. Guo, Z. Qiu and L. Rong, Analysis of an hiv model with immune responses and cell-to-cell transmission, Bull. Malays. Math. Sci. So., 43 (2020), 581-607. doi: 10.1007/s40840-018-0699-5.
[20]	S. A. Kalams, P. J. Goulder, A. K. Shea, N. G. Jones, A. K. Trocha, G. S. Ogg and B. D. Walker, Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy, J. Virol., 73 (1999), 6721-6728. doi: 10.1128/JVI.73.8.6721-6728.1999.
[21]	D. E. Kirschner and G. Webb, Understanding drug resistance for monotherapy treatment of HIV infection, Bull. Math. Biol., 59 (1997), 763-785. doi: 10.1007/BF02458429.
[22]	R. Koup, J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing and D. D. Ho, Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome, J. Virol., 68 (1994), 4650-4655. doi: 10.1128/JVI.68.7.4650-4655.1994.
[23]	M. Louie, Determining the relative efficacy of highly active antiretroviral therapy, J.Infect. Dis., 187 (2003), 896-900. doi: 10.1086/368164.
[24]	L. M. Mansky and H. M. Temin, Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase, J. Virol., 69 (1995), 5087-5094. doi: 10.1128/JVI.69.8.5087-5094.1995.
[25]	S. Marino, I. B. Hogue, C. J. Ray and D. E. Kirschner, A methodology for performing global uncertainty and sensitivity analysis in systems biology, J. Theor. Biol., 254 (2009), 178-196. doi: 10.1016/j.jtbi.2008.04.011.
[26]	R. D. Mason, M. I. Bowmer, C. M. Howley, M. Gallant, J. C. Myers and M. D. Grant, Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 pol epitopes, J. Immunol., 172 (2004), 7212-7219. doi: 10.4049/jimmunol.172.11.7212.
[27]	A. R. McLean and M. A. Nowak, Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV, Aids, 6 (1992), 71-79. doi: 10.1097/00002030-199201000-00009.
[28]	S. H. Michaels, R. Clark and P. Kissinger, Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, New. Engl. J. Med., 339 (1998), 405-406. doi: 10.1056/NEJM199808063390612.
[29]	P. Ngina, R. W. Mbogo and L. S. Luboobi, HIV drug resistance: Insights from mathematical modelling, Appl. Math. Model., 75 (2019), 141-161. doi: 10.1016/j.apm.2019.04.040.
[30]	M. Nowak and R. M. May, Virus Dynamics: Mathematical Principles of Immunology and Virology: Mathematical Principles of Immunology and Virology, Oxford University Press, UK, 2000.
[31]	M. A. Nowak and C. R. Bangham, Population dynamics of immune responses to persistent viruses, Science, 272 (1996), 74-79. doi: 10.1126/science.272.5258.74.
[32]	M. A. Nowak and R. M. May, Mathematical biology of HIV infections: Antigenic variation and diversity threshold, Math. Biosci., 106 (1991), 1-21. doi: 10.1016/0025-5564(91)90037-J.
[33]	M. A. Nowak and A. J. McMichael, How HIV defeats the immune system, Sci. AM., 273 (1995), 58-65. doi: 10.1038/scientificamerican0895-58.
[34]	A. S. Perelson, D. E. Kirschner and R. De Boer, Dynamics of HIV infection of CD4+ T cells, Math. Biosci., 114 (1993), 81-125. doi: 10.1016/0025-5564(93)90043-A.
[35]	A. S. Perelson, A. U. Neumann, M. Markowitz, J. M. Leonard and D. D. Ho, HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time, Science, 271 (1996), 1582-1586. doi: 10.1126/science.271.5255.1582.
[36]	A. S. Perelson and R. M. Ribeiro, Modeling the within-host dynamics of HIV infection, BMC Biol., 11 (2013), 96. doi: 10.1186/1741-7007-11-96.
[37]	Z. Qiu and Z. Feng, The dynamics of an epidemic model with targeted antiviral prophylaxis, J. Biol. Dyn., 4 (2010), 506-526. doi: 10.1080/17513758.2010.498925.
[38]	S. M. Raimundo, H. M. Yang, E. Venturino and E. Massad, Modeling the emergence of HIV-1 drug resistance resulting from antiretroviral therapy: Insights from theoretical and numerical studies, BioSystems, 108 (2012), 1-13. doi: 10.1016/j.biosystems.2011.11.009.
[39]	B. Ramratnam and et al., Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis, The Lancet, 354 (1999), 1782-1785. doi: 10.1016/S0140-6736(99)02035-8.
[40]	R. M. Ribeiro and S. Bonhoeffer, Production of resistant HIV mutants during antiretroviral therapy, P. Natl. A. Sci., 97 (2000), 7681-7686. doi: 10.1073/pnas.97.14.7681.
[41]	R. M. Ribeiro, S. Bonhoeffer and M. A. Nowak, The frequency of resistant mutant virus before antiviral therapy, Aids, 12 (1998), 461-465. doi: 10.1097/00002030-199805000-00006.
[42]	L. Rong, Z. Feng and A. S. Perelson, Emergence of HIV-1 drug resistance during antiretroviral treatment, Bull. Math. Biol., 69 (2007), 2027-2060. doi: 10.1007/s11538-007-9203-3.
[43]	L. Rong, Z. Feng and A. S. Perelson, Mathematical modeling of HIV-1 infection and drug therapy, Math. Model. Bios., 87-131. doi: 10.1007/978-3-540-76784-8_3.
[44]	L. Rong, M. A. Gilchrist, Z. Feng and A. S. Perelson, Modeling within-host HIV-1 dynamics and the evolution of drug resistance: Trade-offs between viral enzyme function and drug susceptibility, J. Theor. Biol., 247 (2007), 804-818. doi: 10.1016/j.jtbi.2007.04.014.
[45]	L. Rong and A. S. Perelson, Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips, Math. Biosci., 217 (2009), 77-87. doi: 10.1016/j.mbs.2008.10.006.
[46]	B. Sebastian and A. N. Martin, Pre-existence and emergence of drug resistance in HIV-1 infection, Proc. R. Soc. Lond. B, 264 (1997), 631-637. doi: 10.1098/rspb.1997.0089.
[47]	A. K. Sewell, D. A. Price, A. Oxenius, A. D. Kelleher and R. E. Phillips, Cytotoxic T Lymphocyte responses to human immunodeficiency virus: Control and escape, Stem Cells, 18 (2000), 230-244. doi: 10.1634/stemcells.18-4-230.
[48]	T. Shiri, W. Garira and S. D. Musekwa, A two-strain hiv-1 mathematical model to assess the effects of chemotherapy on disease parameters, Math. Biosci. Eng., 2 (2005), 811. doi: 10.3934/mbe.2005.2.811.
[49]	M. O. Souza and J. P. Zubelli, Global stability for a class of virus models with Cytotoxic T Lymphocyte immune response and antigenic variation, Bull. Math. Biol., 73 (2011), 609-625. doi: 10.1007/s11538-010-9543-2.
[50]	N. Tarfulea and P. Read, A mathematical model for the emergence of HIV drug resistance during periodic bang-bang type antiretroviral treatment, Involve, J. Math., 8 (2015), 401-420. doi: 10.2140/involve.2015.8.401.
[51]	P. Van den Driessche and J. Watmough, Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission, Math. Biosci., 180 (2002), 29-48. doi: 10.1016/S0025-5564(02)00108-6.
[52]	L. M. Wahl and M. A. Nowak, Adherence and drug resistance: Predictions for therapy outcome, Proc. Biol. Sci., 267 (2000), 835-843. doi: 10.1098/rspb.2000.1079.
[53]	K. Wang, W. Wang and X. Liu, Global stability in a viral infection model with lytic and nonlytic immune responses, Comput. Math. Appl., 51 (2006), 1593-1610. doi: 10.1016/j.camwa.2005.07.020.
[54]	K. Wang, W. Wang, H. Pang and X. Liu, Complex dynamic behavior in a viral model with delayed immune response, Physica D: Nonlinear Phenomena, 226 (2007), 197-208. doi: 10.1016/j.physd.2006.12.001.
[55]	X. Wang, A. Elaiw and X. Song, Global properties of a delayed HIV infection model with CTL immune response, Appl. Math. Comput., 218 (2012), 9405-9414. doi: 10.1016/j.amc.2012.03.024.
[56]	X. Wang, Y. Tao and X. Song, Global stability of a virus dynamics model with beddington-deangelis incidence rate and CTL immune response, Nonlinear Dyn., 66 (2011), 825-830. doi: 10.1007/s11071-011-9954-0.
[57]	Y. Wang, F. Brauer, J. Wu and J. M. Heffernan, A delay-dependent model with HIV drug resistance during therapy, J. Math. Anal. Appl., 414 (2014), 514-531. doi: 10.1016/j.jmaa.2013.12.064.
[58]	Y. Wang, Y. Zhou, F. Brauer and J. M. Heffernan, Viral dynamics model with CTL immune response incorporating antiretroviral therapy, J. Math. Biol., 67 (2013), 901-934. doi: 10.1007/s00285-012-0580-3.
[59]	R. A. Weiss, How does HIV cause AIDS?, Science, 260 (1993), 1273-1279. doi: 10.1126/science.8493571.
[60]	WHO, HIV/AIDS: Key facts, http://www.who.int/news-room/fact-sheets/detail/hiv-aids, 2018.
[61]	D. Wodarz and A. L. Lloyd, Immune responses and the emergence of drug-resistant virus strains in vivo, Proc. R. Soc. Lond. B, 271 (2004), 1101-1109.
[62]	D. Wodarz and M. A. Nowak, Specific therapy regimes could lead to long-term immunological control of HIV, P. Natl. A. Sci., 96 (1999), 14464-14469. doi: 10.1073/pnas.96.25.14464.
[63]	D. Wodarz and M. A. Nowak, Immune responses and viral phenotype: Do replication rate and cytopathogenicity influence virus load?, Comput. Math. Method. M., 2 (2000), 113-127. doi: 10.1080/10273660008833041.
[64]	D. Wodarz and M. A. Nowak, Mathematical models of HIV pathogenesis and treatment, BioEssays, 24 (2002), 1178-1187. doi: 10.1002/bies.10196.
[65]	J. Wu, P. Yan and C. Archibald, Modelling the evolution of drug resistance in the presence of antiviral drugs, BMC Public Health, 7 (2007), 300. doi: 10.1186/1471-2458-7-300.
[66]	J. Wu, R. Dhingra, M. Gambhir and J. V. Remais, Sensitivity analysis of infectious disease models: Methods, advances and their application, J. R. Soc. Interface, 10 (2013), 20121018. doi: 10.1098/rsif.2012.1018.
[67]	Y. Xiao, S. Tang, Y. Zhou, R. J. Smith, J. Wu and N. Wang, Predicting the HIV/AIDS epidemic and measuring the effect of mobility in mainland China, J. Theor. Biol., 317 (2013), 271-285. doi: 10.1016/j.jtbi.2012.09.037.
[68]	H. Zhu and X. Zou, Dynamics of a HIV-1 infection model with cell-mediated immune response and intracellular delay, Discrete Contin. Dyn. Syst. Ser. B, 12 (2009), 511-524. doi: 10.3934/dcdsb.2009.12.511.

Figure 1. The schematic diagram of HIV transmission with wild-type and resistant virus

Figure Options

Download full-size image

Download as PowerPoint slide

Figure 2. The dynamics of infection before converging to steady states. $ (a)-(d) $ represent uninfected cells, wild-type virus, resistant virus, and CTL cells, respectively. The blue solid line is the case in which CTL cells are present. The parameters are from Table 1 and $ b = 0.1 $. We have $ R_{s} = 3.13>R_{r} = 1.74>1 $, $ R_{cs} = 68.1>1 $. Solution trajectories of the system converge to the positive equilibrium $ E^{\star} = (415257, 14994.3, 586870, 1.01219, 26.4110, 44.9845) $. The red dotted line refers to the case in which CTL cells are absent. The parameter $ c $ is 0. This yields $ R_{s} = 3.13>R_{r} = 1.74>1 $, $ R_{cs} = 0<1 $. Solution trajectories of the system converge to the CTL immune-free equilibrium $ E^{f} = (318355, 23056.2, 902393, 1.55640, 40.6104, 0) $

Figure Options

Download full-size image

Download as PowerPoint slide

Figure 3. Sensitivity analysis for four reproduction numbers. (a) The PRCC of $ R_{s} $ for seven parameters, (b) the PRCC of $ R_{r} $ for six parameters, (c) the PRCC of $ R_{cs} $ for nine parameters, and (d) the PRCC of $ R_{cr} $ for eight parameters

Figure Options

Download full-size image

Download as PowerPoint slide

Figure 4. Predicted dynamics of system (4) under treatment. $ (a)-(d) $ represent uninfected cells, wild-type virus, resistant virus, and CTL cells, respectively. The blue solid line represents the case in which CTL cells are present. The parameters given in Table 1 are used and $ b=0.1 $. This yields $ R_{s}^{\prime}=1.57>R_{r}^{\prime}=1.54>1 $ and $ R_{cs}^{\prime}=36.30>1 $. Thus, solutions trajectories of the system converge to the interior equilibrium $ E^{\star\prime}=(733912, 7673.78, 243257, 13.8008, 346.384, 23.0628) $. The red dotted line refers to the case in which CTL cells are absent. Parameters from Table 1 are used and $ b=0.1, c=0 $. In this case, $ R_{s}^{\prime}=1.57>R_{r}^{\prime}=1.54>1 $ and $ R_{cs}^{\prime}=0<1 $. Solutions trajectories of the system converge to the CTL immune-free equilibrium $ E^{f\prime}=(635966, 12174.6, 476875, 21.8671, 571.018, 0) $

Figure Options

Download full-size image

Download as PowerPoint slide

Figure 5. Invasion of drug-resistant virus. (a) Effects of the infection rate $ \beta_{s} $ and overall drug efficacy $ \eta_{s} $ on $ R_{s}^{\prime} $ and $ R_{r}^{\prime} $. (b) The projection of (a) on the $ \beta_{s}-\eta_{s} $ plane. (c) Part of (b) when $ \eta_{s} $ is from 0.4 to 0.6. The vertical line in magenta represents $ \eta_{s} = 0.51 $. In the simulation, we assume that $ \eta_{r} = 0.23\eta_{s}, \beta_{r} = 0.83\beta_{s} $. The other parameters are given in Table 1

Figure Options

Download full-size image

Download as PowerPoint slide

Figure 6. Predicted dynamics of system (4) when drug resistance invades during treatment. Figure $ (a)-(b) $ shows the wild-type virus and the resistant virus, respectively. $ \eta_{s} = 0.6876, \eta_{r} = 0.1635 $, $ R_{s}^{\prime} = 0.9778<1<R_{r}^{\prime} = 1.455, R_{cr} = 312.7>1 $. The solutions of the system converge to the infected equilibrium with drug-resistant strain and CTL immune response $ E^{rc\prime} = (928780, 0, 0, 1756.85, 45817.3, 52.7080) $. Figure $ (c)-(d) $ is similar to $ (a)-(b) $ except $ \eta_{s} = 0.4330, \eta_{r} = 0.0957 $. In this case, $ R_{r}^{\prime} = 1.573<R_{s}^{\prime} = 1.775, R_{cs}^{\prime} = 436.6>1 $. Both strains of virus persist and the solutions of the system converge to the interior equilibrium $ E^{\star\prime} = (872574, 2744.46, 86963.0, 0.722593, 18.1288, 82.2710) $. The parameters are from Table 1

Figure Options

Download full-size image

Download as PowerPoint slide

Figure 7. Dynamics of system (4) with different values of $ c $ (the proliferation rate of CTLs). Green dashed-dot line is for $ c = 0 $, black solid line is for $ c = 0.00003 $, blue dashed line is for $ c = 0.0002 $, and red dot line is for $ c = 0.001 $. We chose $ \eta_{s} = 0.5328, \eta_{r} = 0.1221 $ and the other parameters can be found in Table 1

Figure Options

Download full-size image

Download as PowerPoint slide

Figure 8. Drug resistance dynamics under different drug efficacies. (a) The immune clearance rate is $ b = 0.1 $ and (b) $ b = 0.01 $. Green curve is for $ \eta_{s} = 0.52, \eta_{r} = 0.12 $, red curve is for $ \eta_{s} = 0.69, \eta_{r} = 0.16 $, and blue curve is for $ \eta_{s} = 0.96, \eta_{r} = 0.29 $. $ c $ is fixed at $ 0.001 $ and other parameters are given in Table 1

Figure Options

Download full-size image

Download as PowerPoint slide

Figure 9. (a) The difference between non-infectious and infectious wild-type virus concentrations. (b) The difference between non-infectious and infectious drug-resistant virus concentrations. Shortly after initiation of potent antiretroviral therapy, the difference between non-infectious and infectious viral levels (logarithm with base 10) approaches a constant. The parameters can be found in Table 1

Figure Options

Download full-size image

Download as PowerPoint slide

Table 1. Parameter descriptions and sources for their values

Parameter	Value	Ranges	Description	Reference
$ \lambda $	$ 10^{4}ml^{-1}day^{-1} $	$ 100\sim200000 $	Production rate of uninfected cells	[42]
$ d $	$ 0.01day^{-1} $	$ 0.0001\sim 0.8 $	Death rate of uninfected cells	[34]
$ \beta_{s} $	$ 2.4\times10^{-8}ml\cdot day^{-1} $	$ 10^{-6}\sim2.4\times10^{-6} $	Infection rate of uninfected cells by wild-type virus	[34]
$ \beta_{r} $	$ 2.0\times10^{-8}ml\cdot day^{-1} $	$ 10^{-6}\sim2.0\times10^{-6} $	Infection rate of uninfected cells by drug-resistant virus	[42]
$ \delta $	$ 0.3day^{-1} $	$ 0.1\sim0.9 $	Death rate of infected cells	[42]
$ k $	$ 0.002mm^{3}day^{-1} $	-	Clearance rate of infected cells by CTL killing	[48, 1]
$ p_{s} $	$ 900day^{-1} $	$ 90\sim1000 $	Generation rate of wild-type virus	[8, 17]
$ p_{r} $	$ 600day^{-1} $	$ 60\sim1000 $	Generation rate of drug-resistant virus	[8, 17]
$ d_{1} $	$ 23day^{-1} $	$ 10\sim50 $	Clearance rate of wild-type and resistant virus	[39]
$ c $	$ 0.0003ml^{-1}day^{-1} $	$ 0\sim0.001 $	generation rate of CTL	[55, 61]
$ b $	$ 0.01day^{-1} $	$ 0.01\sim1 $	death rate of CTL	[48, 61]
$ \mu $	$ 3\times10^{-5} $	$ 10^{-6}\sim10^{-4} $	Single mutation rate	[24]
$ \varepsilon_{RTI} $	Varied	$ 0\sim1 $	Efficacy of RTI	see text
$ \varepsilon_{PI} $	Varied	$ 0\sim1 $	Efficacy of PI	see text
$ \sigma_{RTI} $	Varied	$ 0\sim1 $	Resistance ratio of RTI	see text
$ \sigma_{PI} $	Varied	$ 0\sim1 $	Resistance ratio of PI	see text

Table Options

Download as excel

Parameter	Value	Ranges	Description	Reference
$ \lambda $	$ 10^{4}ml^{-1}day^{-1} $	$ 100\sim200000 $	Production rate of uninfected cells	[42]
$ d $	$ 0.01day^{-1} $	$ 0.0001\sim 0.8 $	Death rate of uninfected cells	[34]
$ \beta_{s} $	$ 2.4\times10^{-8}ml\cdot day^{-1} $	$ 10^{-6}\sim2.4\times10^{-6} $	Infection rate of uninfected cells by wild-type virus	[34]
$ \beta_{r} $	$ 2.0\times10^{-8}ml\cdot day^{-1} $	$ 10^{-6}\sim2.0\times10^{-6} $	Infection rate of uninfected cells by drug-resistant virus	[42]
$ \delta $	$ 0.3day^{-1} $	$ 0.1\sim0.9 $	Death rate of infected cells	[42]
$ k $	$ 0.002mm^{3}day^{-1} $	-	Clearance rate of infected cells by CTL killing	[48, 1]
$ p_{s} $	$ 900day^{-1} $	$ 90\sim1000 $	Generation rate of wild-type virus	[8, 17]
$ p_{r} $	$ 600day^{-1} $	$ 60\sim1000 $	Generation rate of drug-resistant virus	[8, 17]
$ d_{1} $	$ 23day^{-1} $	$ 10\sim50 $	Clearance rate of wild-type and resistant virus	[39]
$ c $	$ 0.0003ml^{-1}day^{-1} $	$ 0\sim0.001 $	generation rate of CTL	[55, 61]
$ b $	$ 0.01day^{-1} $	$ 0.01\sim1 $	death rate of CTL	[48, 61]
$ \mu $	$ 3\times10^{-5} $	$ 10^{-6}\sim10^{-4} $	Single mutation rate	[24]
$ \varepsilon_{RTI} $	Varied	$ 0\sim1 $	Efficacy of RTI	see text
$ \varepsilon_{PI} $	Varied	$ 0\sim1 $	Efficacy of PI	see text
$ \sigma_{RTI} $	Varied	$ 0\sim1 $	Resistance ratio of RTI	see text
$ \sigma_{PI} $	Varied	$ 0\sim1 $	Resistance ratio of PI	see text

Table 2. Summary of the stability results of system (1)

Conditions			System (1)
$ R_{0<1} $			$ E^{0} $ $ is $ $ L.A.S $
$ R_{0}>1 $	$ R_{s}<R_{r} $	$ R_{cr<1} $	$ E^{r} $ $ is $ $ L.A.S $
	$ R_{s}<R_{r} $	$ R_{cr>1} $	$ E^{rc} $ $ is $ $ L.A.S $
	$ R_{s}>R_{r} $	$ R_{cs<1} $	$ E^{f} $ $ is $ $ L.A.S $
	$ R_{s}>R_{r} $	$ R_{cs>1} $	$ E^{\star} $ $ is $ $ L.A.S $ $ (\hbox{by simulation}) $

Table Options

Download as excel

Conditions			System (1)
$ R_{0<1} $			$ E^{0} $ $ is $ $ L.A.S $
$ R_{0}>1 $	$ R_{s}<R_{r} $	$ R_{cr<1} $	$ E^{r} $ $ is $ $ L.A.S $
	$ R_{s}<R_{r} $	$ R_{cr>1} $	$ E^{rc} $ $ is $ $ L.A.S $
	$ R_{s}>R_{r} $	$ R_{cs<1} $	$ E^{f} $ $ is $ $ L.A.S $
	$ R_{s}>R_{r} $	$ R_{cs>1} $	$ E^{\star} $ $ is $ $ L.A.S $ $ (\hbox{by simulation}) $

[1]	Lianwen Wang, Zhijun Liu, Yong Li, Dashun Xu. Complete dynamical analysis for a nonlinear HTLV-I infection model with distributed delay, CTL response and immune impairment. Discrete and Continuous Dynamical Systems - B, 2020, 25 (3) : 917-933. doi: 10.3934/dcdsb.2019196
[2]	Aiping Wang, Michael Y. Li. Viral dynamics of HIV-1 with CTL immune response. Discrete and Continuous Dynamical Systems - B, 2021, 26 (4) : 2257-2272. doi: 10.3934/dcdsb.2020212
[3]	Zhijun Liu, Lianwen Wang, Ronghua Tan. Spatiotemporal dynamics for a diffusive HIV-1 infection model with distributed delays and CTL immune response. Discrete and Continuous Dynamical Systems - B, 2022, 27 (5) : 2767-2790. doi: 10.3934/dcdsb.2021159
[4]	Alexander Rezounenko. Stability of a viral infection model with state-dependent delay, CTL and antibody immune responses. Discrete and Continuous Dynamical Systems - B, 2017, 22 (4) : 1547-1563. doi: 10.3934/dcdsb.2017074
[5]	Urszula Ledzewicz, Heinz Schättler. Drug resistance in cancer chemotherapy as an optimal control problem. Discrete and Continuous Dynamical Systems - B, 2006, 6 (1) : 129-150. doi: 10.3934/dcdsb.2006.6.129
[6]	Cristian Tomasetti, Doron Levy. An elementary approach to modeling drug resistance in cancer. Mathematical Biosciences & Engineering, 2010, 7 (4) : 905-918. doi: 10.3934/mbe.2010.7.905
[7]	Avner Friedman, Najat Ziyadi, Khalid Boushaba. A model of drug resistance with infection by health care workers. Mathematical Biosciences & Engineering, 2010, 7 (4) : 779-792. doi: 10.3934/mbe.2010.7.779
[8]	Zhenzhen Chen, Sze-Bi Hsu, Ya-Tang Yang. The continuous morbidostat: A chemostat with controlled drug application to select for drug resistance mutants. Communications on Pure and Applied Analysis, 2020, 19 (1) : 203-220. doi: 10.3934/cpaa.2020011
[9]	Jeng-Huei Chen. An analysis of functional curability on HIV infection models with Michaelis-Menten-type immune response and its generalization. Discrete and Continuous Dynamical Systems - B, 2017, 22 (6) : 2089-2120. doi: 10.3934/dcdsb.2017086
[10]	Jinhu Xu, Yicang Zhou. Bifurcation analysis of HIV-1 infection model with cell-to-cell transmission and immune response delay. Mathematical Biosciences & Engineering, 2016, 13 (2) : 343-367. doi: 10.3934/mbe.2015006
[11]	Jinliang Wang, Lijuan Guan. Global stability for a HIV-1 infection model with cell-mediated immune response and intracellular delay. Discrete and Continuous Dynamical Systems - B, 2012, 17 (1) : 297-302. doi: 10.3934/dcdsb.2012.17.297
[12]	Yu Ji, Lan Liu. Global stability of a delayed viral infection model with nonlinear immune response and general incidence rate. Discrete and Continuous Dynamical Systems - B, 2016, 21 (1) : 133-149. doi: 10.3934/dcdsb.2016.21.133
[13]	Tsuyoshi Kajiwara, Toru Sasaki. A note on the stability analysis of pathogen-immune interaction dynamics. Discrete and Continuous Dynamical Systems - B, 2004, 4 (3) : 615-622. doi: 10.3934/dcdsb.2004.4.615
[14]	Nicolas Bacaër, Cheikh Sokhna. A reaction-diffusion system modeling the spread of resistance to an antimalarial drug. Mathematical Biosciences & Engineering, 2005, 2 (2) : 227-238. doi: 10.3934/mbe.2005.2.227
[15]	Urszula Ledzewicz, Shuo Wang, Heinz Schättler, Nicolas André, Marie Amélie Heng, Eddy Pasquier. On drug resistance and metronomic chemotherapy: A mathematical modeling and optimal control approach. Mathematical Biosciences & Engineering, 2017, 14 (1) : 217-235. doi: 10.3934/mbe.2017014
[16]	Ami B. Shah, Katarzyna A. Rejniak, Jana L. Gevertz. Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases. Mathematical Biosciences & Engineering, 2016, 13 (6) : 1185-1206. doi: 10.3934/mbe.2016038
[17]	Sophia R-J Jang, Hsiu-Chuan Wei. On a mathematical model of tumor-immune system interactions with an oncolytic virus therapy. Discrete and Continuous Dynamical Systems - B, 2022, 27 (6) : 3261-3295. doi: 10.3934/dcdsb.2021184
[18]	Haitao Song, Weihua Jiang, Shengqiang Liu. Virus dynamics model with intracellular delays and immune response. Mathematical Biosciences & Engineering, 2015, 12 (1) : 185-208. doi: 10.3934/mbe.2015.12.185
[19]	Mika Yoshida, Kinji Fuchikami, Tatsuya Uezu. Realization of immune response features by dynamical system models. Mathematical Biosciences & Engineering, 2007, 4 (3) : 531-552. doi: 10.3934/mbe.2007.4.531
[20]	Harsh Vardhan Jain, Avner Friedman. Modeling prostate cancer response to continuous versus intermittent androgen ablation therapy. Discrete and Continuous Dynamical Systems - B, 2013, 18 (4) : 945-967. doi: 10.3934/dcdsb.2013.18.945

2021 Impact Factor: 1.497

Tools

Metrics

Tools

Article outline

Figures and Tables

2021 Impact Factor: 1.497

Tools

Figures and Tables

2021 Impact Factor: 1.497

American Institute of Mathematical Sciences

Modeling within-host viral dynamics: The role of CTL immune responses in the evolution of drug resistance

References:

References:

Tools

Metrics

Other articles
by authors

Tools

Tools

Tools

Metrics

Other articles
by authors

American Institute of Mathematical Sciences

Modeling within-host viral dynamics: The role of CTL immune responses in the evolution of drug resistance

References:

References:

Tools

Metrics

Other articlesby authors

Tools

Tools

Tools

Metrics

Other articlesby authors

Other articles
by authors

Other articles
by authors